Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer

Overview of attention for article published in Clinical Cancer Research, November 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 1 news outlet
twitter: 15 X users
patent: 1 patent

reddit: 1 Redditor
bluesky: 1 Bluesky user

Readers on

mendeley: 20 Mendeley

So far, Altmetric has seen 15 X posts from 15 X users, with an upper bound of 75,702 followers.

Nice to see remission of #lungcancer using T cells engineered with TCR binding NY-ESO-1/LAGE-1a shared epitope. Imagine how strongly this could be boosted with $NWBO dendritic cells. @GlopesMd https://t.co/2emTNMOJ4f https://t.co/YQCurX47ii

Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer | Clinical Cancer Research | American Association for Cancer Research https://t.co/HTctWLC2Le

Pilot Study: Safety and tolerability of Lete-cel in NSCLC. https://t.co/4SHhgFVZJo https://t.co/HrnIOQEYBT

IMMUNOTHERAPY: autologous T cells engineered to express a NY-ESO-1/LAGE-1a T cell receptor were well tolerated but delivered only modest efficacy in a phase 1 study of NSCLC (ORR 6%). https://t.co/xNm1E4xpiU

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 11 additional X posts.